1,193 results on '"Van Assche G"'
Search Results
102. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnʼs disease after failure of two other anti-TNF antibodies
103. Biologicals: old and new ones
104. Characterization of Reacting Polymer Systems by Temperature-Modulated Differential Scanning Calorimetry
105. Outcome of surgery for rectovaginal fistula due to Crohnʼs disease
106. Modulated temperature differential scanning calorimetry: Considerations for a quantitative study of thermosetting systems
107. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn’s disease patients eligible for anti-α4 integrin therapy?
108. Ustekinumab as induction and maintenance therapy for Ulcerative Colitis
109. altering the natural history of Crohnʼs disease – evidence for and against current therapies
110. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
111. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
112. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease
113. Involvement of 4-1BB (CD137)–4-1BBligand interaction in the modulation of CD4+ T cell-mediated inflammatory colitis
114. infliximab therapy for inflammatory bowel disease – seven years on
115. The impact of major depressive disorder on the short- and long-term outcome of Crohnʼs disease treatment with infliximab
116. Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn’s disease
117. The risk of post-operative complications associated with infliximab therapy for Crohnʼs disease: a controlled cohort study
118. Involvement of interleukin 18 in Crohnʼs disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models
119. Treatment of active Crohnʼs disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study
120. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease
121. Motilin receptor density in inflamed and noninflamed tissue in rabbit TNBS-induced colitis
122. Contractile effects and intracellular Ca2+ signalling induced by motilin and erythromycin in the circular smooth muscle of human colon
123. Serum proteomic analysis characterises newly diagnosed Crohn's disease and ulcerative colitis depending on the age at diagnosis
124. Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial
125. Gene expression profiles in inflamed colonic biopsies from newly diagnosed Crohn's disease and ulcerative colitis patients differ depending on the age at diagnosis
126. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease
127. Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI
128. Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI
129. Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance Study
130. CAPNOGRAPHY DURING ENDOSCOPY – A VALUE-BASED HEALTHCARE PILOT IN A HIGH-VOLUME GASTROENTEROLOGY PRACTICE
131. DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
132. P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn’s disease
133. DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
134. OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
135. P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study
136. P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
137. P820 Molecular changes in non-inflamed terminal ileum in patients with ulcerative colitis
138. DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients
139. P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?
140. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
141. P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients
142. P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
143. P001 Multi-omic data integration assisted identification of molecular features contributing to disease heterogeneity in Crohn's disease
144. P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
145. DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience
146. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
147. P155 Adherence to quality indicators among patients with inflammatory bowel disease: an international comparative analysis
148. Modeling and experimental verification of the kinetics of reacting polymer systems
149. Interphase formation in model composites studied by micro-thermal analysis
150. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.